These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10932925)

  • 61. Niacin in patients with diabetes mellitus and coronary artery disease.
    Lavie CJ; Milani RV
    Am J Cardiol; 2001 May; 87(9):1137-8. PubMed ID: 11396426
    [No Abstract]   [Full Text] [Related]  

  • 62. Progression to hepatitis and fibrosis secondary to lomitapide use: selecting the next course of action.
    Miyares MA
    JAMA Intern Med; 2014 Sep; 174(9):1522. PubMed ID: 25178868
    [No Abstract]   [Full Text] [Related]  

  • 63. Progression to hepatitis and fibrosis secondary to lomitapide use--reply.
    Sacks FM; Stanesa M; Hegele RA
    JAMA Intern Med; 2014 Sep; 174(9):1522-3. PubMed ID: 25178869
    [No Abstract]   [Full Text] [Related]  

  • 64. [Dietetic treatment of the hyperlipoproteinemias].
    Rigolfas R; Clapés J
    Rev Enferm; 1990 Apr; 13(140):81-4. PubMed ID: 2356417
    [No Abstract]   [Full Text] [Related]  

  • 65. [Idiopathic hypertriglyceridemia].
    Hirata K
    Nihon Rinsho; 2007 Jul; 65 Suppl 7():329-32. PubMed ID: 17824052
    [No Abstract]   [Full Text] [Related]  

  • 66. [Treatment of hypertriglyceridemia. Current aspects].
    Malaguarnera M; Giugno I; Ruello P; Vinci E; Panebianco MP; Motta M
    Recenti Prog Med; 2000; 91(7-8):379-87. PubMed ID: 10932925
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hypertriglyceridemia: management of atherogenic dyslipidemia.
    Bersot T; Haffner S; Harris WS; Kellick KA; Morris CM
    J Fam Pract; 2006 Jul; 55(7):S1-8. PubMed ID: 16822443
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 71.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 72.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.